Twist Bioscience

#4749

Rank

$1.81B

Marketcap

United States

Country

Leadership team

Dr. Emily Marine Leproust Ph.D. (Co-Founder, Chairman & CEO)

Dr. Patrick John Finn Ph.D. (Pres & COO)

Mr. James M. Thorburn (Chief Financial Officer)

Products/ Services

Biotechnology, Chemical, Health Care, Life Science

Number of Employees

500 - 1000

Headquarters

San Francisco, California, United States

Established

2013

Company Registration

SEC CIK number: 0001581280

Revenue

100M - 500M

Traded as

TWST

Social Media

URL

https://www.twistbioscience.com

Overview

Location

Recognition and Award

References

Summary

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

History

Twist Bioscience was founded in 2013 in the Silicon Valley. The mission of the company has been to accelerate science and innovation through rapid, high quality Synthetic DNA. Since then, the company has grown exponentially, providing Synthetic DNA at scale and expanding both its capabilities and its catalog of products.

Mission

Twist Bioscience's mission is to become the industry leader in synthetic DNA, delivering products for life science research, applied markets, and bioproduction applications that enable a more sustainable world.

Vision

Twist Bioscience's vision is to become the world's leading provider of synthetic DNA and to revolutionize the way in which DNA is accessed, designed and manufactured.

Key Team

Dr. William Charles Banyai Ph.D. (Sr. VP of Advanced Devel., GM of Data Storage & Director)

Ms. Paula Green (Sr. VP of HR)

Ms. Erin Smith (Sr. VP of Gov. Affairs & Public Policy)

Mr. Kevin B. Yankton (VP & Chief Accounting Officer)

Mr. Siyuan Chen (Chief Technology Officer)

Dr. Aaron K. Sato Ph.D. (Chief Scientific Officer)

Mr. Dennis Cho (Sr. VP, Gen. Counsel, Chief Ethics & Compliance Officer)

Recognition and Awards

Twist Bioscience is the recipient of numerous awards, including being named to the prestigious CNBC Disruptor 50 list and the CB Insights 2019 AI 100 list. The company has also been named one of the “50 On Fire” companies of 2016 by the San Francisco Business Times, honored by Global Doing Business as an Industry Innovator, and awarded 2017 and 2018 StartUs Insights Innovation Awards.